Jiang et al. observed that treatment with Pembrolizumab in NCI-H460 lung cancer cells and ZR-75-30 breast cancer cells produced a depletion of miR-20b-5p expression (measured by Real-Time Polymerase Chain Reaction, RT-PCR) and proteins PD-L1 and PD-1 (measured by Western blot). Here, PDCD1 is linked to breast cancer.